spacer
home > ebr > spring 2002 > canada - the number one country for conducting biomedical r&d
PUBLICATIONS
European Biopharmaceutical Review

Canada - The Number One Country for Conducting Biomedical R&D

While lower cost is a compelling reason for conducting R&D in Canada, it is just one of several. Other factors include:

Canada is home to one of the largest, most developed biotech sectors in the world

The potential for partnerships with biotech firms undertaking cutting edge R&D exists throughout Canada

Government funding and tax credits for R&D is generous

Regulations are science-based and conducive to commercialising new products

Social and demographic features make Canada an excellent place to conduct clinical trials

Market-size is enormous, since Canada as a member of the North American Free Trade Agreement (NAFTA) has increased access to both the US and Mexican marketplace


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Michael Rappaport, Publications Supervisor at BIOTECanada Michael Rappaport is the Editor of BIOTECanada Insights, a bilingual, biannual magazine designed to promote the Canadian biotech sector, and BIOTECanada Monthly Reporter, an industry newsletter that provides updates on government relations activities and communications initiatives. Before assuming the position of Publications Supervisor at BIOTECanada, Michael was a Science Writer for the Natural Science and Engineering Research Council, the main funding body for biological, chemical, physical and engineering sciences in Canada. He has a BA Honours degree in English Literature and Political Science, and a Master of Journalism from Carleton University in Ottawa.
spacer
Michael Rappaport
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Innovative Micro-Infusion Pump for Gerresheimer Subsidiary Sensile Medical Developed and Successfully Launched for EVER Pharma

Düsseldorf/Olten, July 03, 2019 – Developed specially by Sensile Medical for EVER Pharma under the brand name D-mine®, this wearable microinfusion pump recently received European CE certification and has already been launched in several European countries. The compact, patient-friendly infusion pump is used for the continuous subcutaneous administration of drugs to treat Parkinson’s disease. The first micro pump from Gerresheimer subsidiary Sensile Medical to be available on the market, it gives Parkinson’s patients greater independence in their day-today lives.
More info >>

White Papers

Sterile Vials Made of Tubular Glass

Gerresheimer AG

Gx® RTF vials powered by Ompi EZ-fill® enhance flexibility by facilitating packaging needs from clinical stage to industrialization with the common goal to minimize customer product risks and optimize total cost of ownership. Gerresheimer combines the competencies in converting glass tubes to serum/ injection vials and ready-to-fill processing for our pharma and biotech customers.
More info >>

 
Industry Events

BioPharm America™ 2019—12th Annual International Partnering Conference

11-12 September 2019, Boston Convention and Exhibition Center (BCEC), Boston, MA 02210 USA

BioPharm America™ is a unique partnering event that forms the nexus of discovery and realization. Startup companies, established biotech and entrepreneurs from academia attend in search of finance, pharma and development partners. The event format highlights innovation and promotes new business relationships by bringing dealmakers from the life science ecosystem together to engage and de-risk the enormous task of drug development. Life science executives from around the world gather to identify, meet and to enter into strategic relationships facilitated by partneringONE®, the world’s leading web-based partnering system. BioPharm America is the only event in North America based on the same reputable formula as EBD Group’s acclaimed European events BIO-Europe® and BIO-Europe Spring®. BioPharm America annually attracts 800+ delegates from over 500 companies who participated in 2,300+ scheduled one-to-one meetings. BioPharm America is now part of Biotech Week Boston, and together they draw a total of over 4,500 life science leaders, scientists and innovators.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement